Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,846,618

« Back to Dashboard
Patent 8,846,618 protects SAXENDA and VICTOZA and is included in two NDAs.

This patent has nine patent family members in nine countries.

Summary for Patent: 8,846,618

Title:Stable formulation of modified GLP-1
Abstract: Pharmaceutical formulations of GLP-1 compounds and methods for preparation thereof.
Inventor(s): Flink; James M. (Klanpenborg, DK), Larsen; Silke Moller (Charlottenlund, DK), Jensen; Simon Bjerregaard (Frederiksberg, DK), Engelund; Dorthe Kot (Holte, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:12/785,861
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 0th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novo Nordisk Inc
liraglutide recombinant
SOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYes8,846,618Jun 27, 2022Y
Novo Nordisk Inc
liraglutide recombinant
SOLUTION;SUBCUTANEOUS022341-001Jan 25, 2010RXYes8,846,618Jun 27, 2022Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,846,618

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark2001 01010Jun 28, 2001
Denmark2001 01011Jun 28, 2001
Denmark2001 01052Jul 4, 2001

International Patent Family for Patent: 8,846,618

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan2004535442► subscribe
Japan5562510► subscribe
Japan2012051894► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.